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Background: Randomized controlled trials, evidence-based medicine, clinical guidelines, and 
total quality management are some of the approaches used to render science-based health care 
services. The clinical pathway for hospitalized patients suffering from acute exacerbations of 
chronic obstructive pulmonary disease (AECOPD) is poorly established, although a clinical 
pathway is an integral part of total quality management.
Aim: To evaluate the outcomes of patients hospitalized with AECOPD in Japan, treated with 
a clinical pathway following published guidelines.
Methods: Prospective data were collected for patients with AECOPD admitted to a general 
hospital over a 5-year period since 2003. The clinical pathway was designed to establish general 
rules for the entire treatment protocol. The clinical pathway indicates which treatments and 
interventions should be performed, and when. In this study, health care providers were required 
to check the clinical pathway sheets to determine the next step of treatment.
Results: This study analyzed 276 hospitalizations in 165 patients. The clinical pathway was 
interrupted and defined as a dropout in 45 cases (16.3%). Nine patients died during hospitalization 
(3.3%). Oxygen was administered in 232 hospitalizations (84.1%). Noninvasive positive pressure 
ventilation (NPPV) treatment was administered in 110 hospitalizations (39.9%). The rate of 
intubation in those cases where NPPV treatment had been administered was 8.2% (9 cases out 
of 110). The average length of stay (LOS) was 20.3 days, and the median value was 15 days. 
The LOS was longer than 30 days in 34 admissions (12.3%), mainly due to complications.
Conclusion: AECOPD can be managed using a clinical pathway. This clinical pathway could 
fill the gap between guidelines and clinical practice.
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Background
Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is one of the 
most common causes of acute hospital admission. These hospital admissions come 
with a high mortality rate and an extended impairment of the health status. Similar 
to diseases like pneumonia, acute myocardial infarction, and heart failure, AECOPD 
is common, has high morbidity, and is costly to society. However, unlike these other 
diseases, the underlying medical conditions responsible for AECOPD are generally 
unknown. Clinical guidelines have been published and updated to standardize the 
  management of AECOPD, with the aim of improving health care and safely reducing 
costs.1   However, the UK National COPD Audit 2003 reported a wide variation in both 
the length of stay (LOS) and mortality among hospitals in the UK.2 The contributing 
  factors remain unclear, although it appears that some of this variation can be attributed International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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to patient factors. In 2006, Lindenauer and colleagues 
reported that only two-thirds of patients with AECOPD 
received the entire set of recommended care protocols in US 
hospitals,3 and that numerous participants received tests or 
treatments that were considered not beneficial. Mularski and 
colleagues also concluded in 2006 that AECOPD patients in 
the US received only 60.4% of the recommended care.4
Randomized controlled trials, evidence-based medicine, 
clinical guidelines, and total quality management are 
considered to be important methods to provide more science-
based health care services. Integrated care pathways or clinical 
pathways detail tasks, sequences, timescales, and disciplines, 
and contain a checklist of all necessary actions.5 It was 
reported in 1998 that AECOPD should be included in the 
table of integrated care pathways in use in Britain.5 In other 
words, clinical pathways may be guidelines or management 
rules within individual hospitals, and are part of a total 
quality management approach to care. They aim to facilitate 
the introduction of clinical guidelines as well as systematic, 
continuing audits into clinical practice; thus, clinical pathways 
can provide a link between establishing clinical guidelines and 
practicing them. A clinical pathway is generally recommended 
in all common clinical settings, especially for scheduled 
admissions such as elective surgery.
Few reports exist on the use of clinical pathways in the 
management of AECOPD. The lack of established clinical 
pathways for AECOPD patients may be due to the difficulty 
associated with setting up a clinical pathway for acute or 
severe illnesses and critical care medicine, and to concerns 
about treatment failure. In addition, the number of patients 
hospitalized with AECOPD is still relatively low in Japan, 
although the prevalence of COPD in Japan has been reported 
to be similar to that of Western countries, based on general 
population studies.6 This low incidence might be another 
reason for the lack of an organized effort to establish a clini-
cal pathway for AECOPD in Japan.
We hypothesized that AECOPD could be treated using a 
clinical pathway, and that it could fill the gap between guide-
lines and clinical practice. In the present study, we developed 
a clinical pathway and applied it to treat patients hospital-
ized with AECOPD in a general hospital in Japan. We then 
analyzed the results of 5 years of prospective observations 
on AECOPD patients treated with this clinical pathway.
Materials and methods
Development of the clinical pathway
The present study was conducted at the Respiratory Division 
of Kyoto-Katsura Hospital, a general hospital that provides 
health care mainly for the western part of the city of Kyoto. 
The clinical pathway was developed in November 2002, and 
was implemented for the care of patients hospitalized with 
AECOPD. The clinical pathway was formalized by a multi-
disciplinary study group made up of pulmonary specialists, 
staff nurses, physiotherapists, pharmacists, emergency staff, 
and dieticians. The clinical pathway indicates which treat-
ments and interventions should be performed, and when. 
In this study, the health care providers were required to check 
the clinical pathway sheets to determine the next step of 
treatment. The clinical pathway was approved by the clinical 
pathway committee responsible for the medical governance 
of the hospital.
The implemented clinical pathway for AECOPD   consists 
of the following interventions: (1) frequent   evaluations 
and laboratory testing, (2) pharmacological treatment, 
(3) instructions on the method of drug administration by a 
ward pharmacist, (4) respiratory management, (5)   pulmonary 
rehabilitation during the acute phase, (6) nutritional   support, 
and (7) early discharge planning. The core therapeutic 
interventions included in the clinical pathway are summarized 
in Table 1. In addition, the plan for antibiotics administra-
tion was adjusted based on the results of blood tests for 
inflammatory markers, a sputum test, and signs of pneumonia 
at 4 and 8 days after beginning the treatment. Intravenous infu-
sions of aminophylline and the administration of expectorants 
were not included in the clinical pathway. As a general rule, 
when the patients were under respiratory management, such 
as oxygen administration and noninvasive positive pressure 
ventilation (NPPV) treatment, arterial blood gas analysis 
was performed every morning and at 30–120 minutes after 
changing the oxygen dose or NPPV setting. To respond to 
acute exacerbations of the patient’s condition, the nurses were 
instructed to change the applied concentration of oxygen as 
follows: if a saturation of peripheral oxygen (SpO2) ,88% 
continues for over 30   minutes, then increase the fraction 
of inspired oxygen (FiO2) one step at a time using the 
  Ventimask®; if a SpO2 . 93% continues over 30 minutes, 
then decrease the FiO2 one step at a time using the Ventimask. 
The initial   setting for NPPV was an inspiratory positive 
airway pressure (IPAP) of 8 cm H2O, an expiratory positive 
airway pressure (EPAP) of 4 cm H2O, a backup respiratory 
rate of 12 breaths per minute, and oxygen supplementation 
to maintain the oxygen concentration before NPPV therapy. 
Hypercapnia was managed by an increase in the IPAP from 
2 to 4 cm H2O after every arterial blood gas analysis. The 
final IPAP was 14–20 cm H2O in most hypercapnic subjects. 
The nurses were responsible for changing the oxygen dose International Journal of COPD 2011:6
Table 1 Therapeutic interventions included in the clinical pathway 
for the management of hospitalized patients with acute exacerbation 
of chronic obstructive pulmonary disease
1. Frequency of the evaluations and testing:
 •    Blood tests, chest x-rays, and ABG analyses on the first, fourth, 
eighth, and 13th day of the exacerbation
 •  ABg analysis every morning if necessary
 •    Pulmonary function tests after inhalation of 200 μg salbutamol 
using an MDI with a spacer on the day after completion of the oral 
glucocorticosteroid course, or before discharge
2. Pharmacological treatment:
 •    high-dose, frequent inhalation of a bronchodilator under 
supervision (introduce  and change to  in a few days)
      Repeated inhalation of 0.5 mL salbutamol using a nebulizer  
every hour
      Repeated inhalation of four puffs of salbutamol (400 μg) + four 
puffs of oxitropium bromide (400 μg) using an MDI and a spacer 
every 2 hours
 •    Oral administration of 0.5 mg/kg of prednisolone every morning for 
10–14 days
 •    Antibiotics administration until the inflammatory markers disappear 
(cefazolin or piperacillin 1– 2 g × 2 div)
 •    Starting inhaled corticosteroids as maintenance therapy after the 
completion of systemic corticosteroid administration
3. Respiratory management:
 •    Oxygen administration at the lowest concentration possible to 
maintain a PaO2 $ 60 mm hg (start with a Ventimask®)
 •    Start NPPV therapy if PaCO2 $ 45(–50) mm hg or if ph drops to 
below 7.35, regardless of the oxygen concentration
4. Pulmonary rehabilitation during the acute phase:
 •  Visit by a physical therapist and rehabilitation at an early stage
5. Instructions on the methods of administration by a ward pharmacist
 •    In the case of breathing difficulties, a single dose of salbutamol by 
nebulizer, or 400 μg salbutamol and 400 μg oxitropium bromide by 
an MDI
 •    When changing to therapy using an MDI and a spacer to 
maintenance therapy including inhaled corticosteroids
 •    Inhalation techniques to be supervised by nurses following a 
standard checklist
6. Planning for an early discharge
7.   Provision of a high-calorie diet and nutrition counseling when necessary
Abbreviations:  ABg,  arterial  blood  gas;  MDI,  metered-dose  inhaler;  NPPV, 
noninvasive positive pressure ventilation; PaCO2, pressure of carbon dioxide in 
arterial blood; PaO2, pressure of oxygen in arterial blood.
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during NPPV therapy as follows: if an SpO2 , 88% continues 
over 30   minutes, then increase the FiO2 by 5% or increase 
the oxygen supplementation by 0.5 L/min; if a SpO2 . 93% 
continues over 30 minutes, then decrease the FiO2 by 5% or 
lower the oxygen supplementation by 0.5 L/min.
The use of pulmonary rehabilitation during the acute 
phase of AECOPD is still controversial. Evidence is accumu-
lating for the effectiveness of pulmonary rehabilitation   during 
the recovery phase of AECOPD.7 However, the optimal 
time to start pulmonary rehabilitation has not been clearly 
established. In the present clinical pathway, a   physiotherapist 
performed the pulmonary rehabilitation as early as possible 
after the vital signs became stable. The Barthel index was 
recorded prior to pulmonary rehabilitation,8 and the 6-minute 
walking test was performed as much as possible before and 
after the pulmonary rehabilitation. Although there is no 
evidence for nutritional interventions to manage AECOPD, 
a high-calorie diet was provided for all subjects, with nutri-
tional counseling as necessary. Early discharge was carefully 
planned in all cases. At the time of discharge, the patients 
were further educated by instructional videos.
Subjects
This study examined those patients who were hospitalized 
during the 5½-year period between January 2003 and June 
2008, and who were treated according to the clinical pathway 
for AECOPD. The inclusion criteria for this clinical pathway 
were: (1) a clinical diagnosis of COPD, (2) a history of smok-
ing (10 pack-years or greater), (3) a forced expiratory volume 
in one second to forced vital capacity ratio (FEV1/FVC) , 0.7 
on or before the first day of the clinical pathway, (4) the 
absence of previous inflammatory changes on chest radio-
graphs that influenced pulmonary function (for example, 
previous thoracoplasty or tubercular sequelae), and (5) the 
presence of aggravated symptoms of COPD compatible with 
exacerbations. Since the confirmation of airflow limitation as 
defined by a FEV1/FVC , 0.7 was necessary for inclusion, the 
results of previous spirometric tests were obtained whenever 
possible. Spirometry was required for admission even if the 
condition was severe, unless previous compatible spirometric 
results were available before admission.
The exclusion criteria were: (1) intubation on the first day 
of disease, (2) tracheotomy prior to the first day of disease, 
(3) exacerbation due to pneumothorax, and (4) exacerbation 
due to cardiac failure alone. When continuous treatment with 
a clinical pathway became impossible due to progression 
of the disease or complications, the case was defined as a 
dropout (variance).
It is well known that COPD patients suffer from the compli-
cation of community-acquired pneumonia at a high frequency. 
It is believed that therapeutic management of AECOPD with 
no clinical signs of pneumonia should be the same as that 
for an exacerbation of COPD as a result of pneumonia.9 In 
addition, it would be under-treatment if those patients with 
exacerbated COPD due to pneumonia were treated only for 
their pneumonia. Therefore, in the current clinical pathway, 
we decided to widen the selection criteria in this regard, and 
included not only AECOPD patients due to respiratory infection, 
but also patients with COPD complicated by pneumonia.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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In addition, we retrospectively examined as many hospital 
records as possible during the study period, and collected 
information on COPD patients who were not included in 
the clinical pathway.
Results
The present clinical pathway was applied to a total of 300 
hospitalizations for 189 patients. Although we screened 
the patients based on the exclusion criteria before the clinical 
pathway was initiated, we found 11 cases where the clinical 
pathway for AECOPD was inappropriately applied. The most 
frequent reason for an error in the initial screening was that 
the patient was a never-smoker, and the attending physician 
applied the clinical pathway without confirming the smoking 
history. The second reason was that the spirometric results 
were not available, and that the airflow limitation was not 
confirmed before the initiation of the clinical pathway. These 
cases were excluded from our analysis.
In addition, 13 subjects were excluded from further 
  analysis due to a disappearance of their airflow limitation. 
These patients successfully passed the initial screening, and an 
airflow limitation was confirmed at the initiation of the   clinical 
pathway. Nevertheless, the spirometry performed before 
discharge revealed that the FEV1/FVC was over 0.7 (ranging 
from 70.6% to 94.5%). These patients were diagnosed with 
a reversible airflow limitation whose initial presentation was 
similar to AECOPD. We believe that these cases could not 
be excluded initially due to the difficulty in distinguishing an 
asthma exacerbation from an AECOPD in some patients.
Thus, the remaining 276 hospitalizations of 165 patients 
were analyzed in the present study. The results are summarized in 
Table 2. The average age of the patients, calculated with the total 
number of hospitalizations as the denominator, was 74.6 years. 
In 97 cases (35.1%), the patients were taken to the hospital by 
ambulance, and in 83 cases (30.0%), since the chest radiographs 
revealed infiltration compatible with pneumonia, they were 
diagnosed with a pneumonic exacerbation of COPD.
Spirometry was performed in 248 out of 276 episodes 
after completing the treatment, and disease severity of COPD 
was unknown in 28 hospitalizations (10.1%). According to 
the GOLD (Global Initiative for Chronic Obstructive Lung 
Disease) criteria,1 there were 29 (10.5%), 81 (29.3%), 89 
(32.2%), and 49 (17.8%) episodes, respectively, of stage I, 
II, III, and IV . The post-bronchodilator FEV1 was 0.99 L on 
average, and the FEV1/FVC was 44.4%. The average LOS 
was 20.3 days, and the median value was 15 days. The length 
of stay was longer than 30 days in 34 admissions (12.3%), 
mainly due to complications.
Table 2 Characteristics of a total of 276 episodes from 165 patients treated by the clinical pathway for acute exacerbations of chronic 
obstructive pulmonary disease
Number %
gender (Male) 234 84.8
Smoking condition (Current) 51 18.5
Pneumonia as a complication (Present) 83 30.1
Ambulance transportation (yes) 97 35.1
Mean Median SD
Age (years) 74.6 75.0 8.5
history of smoking (pack-years) 71 59 40
Length of stay (days) 20.3 15.0 18.9
Arterial blood gas before beginning treatment with variable concentration of oxygena
PaO2 (mm hg) 64.5 58.5 29.4
PaCO2 (mm hg) 47.4 40.4 18.4
Ph 7.397 7.419 0.082
Pulmonary function tests after treatmentb
FeV1 (L) 0.99 0.87 0.46
FeV1 (% predicted) 51.0 45.9 23.8
FeV1/FVC (%) 44.4 41.3 14.3
FVC (L) 2.24 2.15 0.73
FVC (% predicted) 75.6 76.7 21.2
Barthel indexc (score, 0–100) 60.1 65.0 31.3
6MWD before rehabilitationd (meter) 199 175 143
6MWD after rehabilitatione (meter) 268 270 140
Notes: an = 275; bn = 248; cn = 245; dn = 210; en = 210.
Abbreviations: 6MWD, 6-minute walk distance; FeV1, forced expiratory volume in one second; FVC, forced vital capacity; PaCO2, pressure of carbon dioxide in arterial 
blood; PaO2, pressure of oxygen in arterial blood; SD, standard deviation.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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The clinical pathway was completed in 231 out of 276 
hospitalizations (83.7%), but was interrupted and regarded 
as a dropout in 45 hospitalizations (16.3%), see Table 3. 
Nine patients (3.3%) died during hospitalization due to the 
following   reasons: two cases each of pneumothorax-related 
deaths, septic shock, and cerebral infarction; one case each 
of   nosocomial pneumonia, unconsciousness of unknown 
cause, and sudden death of unknown cause. One of the two 
pneumothorax-related deaths occurred in a subject that had a 
bilateral pneumothorax that developed just after the introduc-
tion of NPPV; he received subsequent mechanical ventilation 
with intubation, but the treatment was unsuccessful. In the 
second pneumothorax-related death, an autopsy revealed a 
collapse of the left lung in a patient who died unexpectedly on 
the third day after   hospitalization. All of the fatal cases were 
due to   complications after the initiation of the treatment, and 
were difficult to predict. Seven patients (2.5%) were trans-
ferred to other long-term care facilities; four had families 
who refused their discharge to home, and the remaining three 
were transferred due to complications (intertrochanteric hip 
fracture, cerebral infarction, and interstitial pneumonia).
In 29 out of 45 dropouts, the patients did not complete 
the clinical pathway but were discharged home from the 
hospital after receiving various subsequent therapies. Among 
the 29 dropouts who were discharged from the hospital, in 
nine hospitalizations, the reason for the dropout was only 
because the pulmonary rehabilitation was not performed, 
even though all other procedures scheduled in the clinical 
pathway were completed. The other reasons for the   dropouts 
were complications that appeared during the clinical pathway, 
including pneumonia in five cases, pleural effusion in three 
cases, a pneumothorax in two cases. Nine cases that required 
intubation and the use of a mechanical ventilator following 
unsuccessful NPPV treatment were also included in the 
dropouts.
Oxygen was administered to 232   hospitalizations 
with a pressure of oxygen in arterial blood (PaO2) , 
60 mm Hg (84.1%). NPPV treatment was administered in 
110   hospitalizations with a pressure of carbon dioxide in 
arterial blood (PaCO2) $45(–50) mm Hg or a pH , 7.35 
(39.9%). Forty-four hospitalizations without respiratory 
failure (15.9%) were treated without oxygen administration 
and without NPPV treatment, and 122 hospitalizations with a 
PaO2 , 60 mm Hg but without a PaCO2 $ 45(–50) mm Hg or 
a pH , 7.35 (44.2%) were treated with oxygen   administration 
but without NPPV treatment. There were only three dropouts 
(6.8%) among these 44 hospitalizations without oxygen 
administration and without NPPV treatment. There were 
13 cases (10.7%) of dropouts among the 122 hospitalizations 
with oxygen administration but without NPPV   treatment. 
On the other hand, there were 29 dropouts (26.4%) out of 
110 hospitalizations with oxygen administration and NPPV 
treatment. Therefore, the clinical pathway completion rates 
were 93.2%, 89.3%, and 73.6%, respectively, for these 
Table 3 Outcomes of COPD-related hospitalizations during the study period
n = 300 The clinical pathway applied
n = 11 entry criteria violation
n = 13 Disappearance of airflow limitation after discharge
n = 45 Dropout
n = 9 Died
n = 7 Transferred to other long-term care facilities
n = 29 Discharged to home from the hospital alive
n = 231 Treatment with the clinical pathway completed
n = 44 Without oxygen, without NPPV
n = 122 With oxygen, without NPPV
n = 110 With oxygen, with NPPV
n = 62 COPD-related hospitalizations outside the clinical pathway
n = 25 AeCOPD outside the clinical pathway
n = 9 Intubations on the first day of exacerbation
n = 1 Tracheotomy prior to the first day of exacerbation
n = 3 exacerbations due to pneumothorax
n = 2 exacerbations due to cardiac failure alone
n = 10 Prompt discharge because of very mild exacerbations
n = 37 Other reasons
Abbreviations: AeCOPD, acute exacerbation of chronic obstructive pulmonary disease; COPD, chronic obstructive pulmonary disease; NPPV, noninvasive positive 
pressure ventilation.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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hospitalization groups. The rate of intubation in those cases 
where NPPV treatment had been administered once was 
8.2% (9 cases out of 110).
Pulmonary rehabilitation was administered in 262 
cases, and started on average 3.5 days (median 3 days) 
after   admission. The Barthel index was recorded in 245 
  episodes, and the mean ± standard deviation index value was 
60.1 ± 31.3, ranging from 0 to 100. The six-minute walking 
distance was 199 ± 533 and 268 ± 660 meters in 210 episodes 
before versus after pulmonary rehabilitation, respectively.
We examined the hospital records and found a total of 
62 COPD-related hospitalizations that were not treated using 
the clinical pathway. Among these 62 episodes, we could 
identify the reason why the clinical pathway was not applied 
in 25 AECOPD episodes. In the remaining 37 episodes, it 
was not clear from the medical records whether the COPD 
was stable or not, and it was difficult to identify the reason 
why the clinical pathway was not applied, even though these 
cases appeared to match the criteria for AECOPD.
Discussion
Our analysis of AECOPD patients treated by a newly devel-
oped clinical pathway revealed two important findings. First, 
AECOPD can be effectively treated using a clinical pathway. 
Since all of the participants received all of the interventions 
listed in the clinical pathway, this pathway proved to be well 
tolerated and accepted, even in critically ill patients with 
AECOPD. The fact that we could apply all of the listed inter-
ventions to all of the patients suggests that the quality of care 
provided in our hospital had improved compared with the 
level of care before the introduction of the clinical pathway. 
Second, the rate of dropouts from the clinical pathway was 
relatively low (approximately 16%), and most of the dropouts 
were hypercapnic cases that required NPPV treatment. This 
low dropout rate suggests that the clinical pathway was highly 
adaptable to all patient conditions. The mortality rate during 
hospitalization was less than 5% in the present study, further 
supporting the contention that the clinical pathway was safe 
and did not impose any significantly adverse effects, even 
on severely ill patients. Unfortunately, it was impossible 
to compare the present study with a control group treated 
without the clinical pathway, because the present study was 
not a randomized controlled trial.
AECOPD represents an extremely severe event that can 
occur at any point during the long course of COPD. AECOPD 
can be lethal, and can impair a patient’s health-related quality 
of life severely and permanently. Thus, the first important 
step is to take measures to prevent AECOPD from occurring 
among patients with stable COPD. A comprehensive 
approach, including the use of drugs known to reduce the 
frequency of AECOPD episodes, is necessary.10 As the second 
step, if AECOPD does occur, then it is important to promptly 
change the therapeutic regimen, and, if necessary, facilitate 
the patient’s access to medical services. Patient education 
and self-management involving action plans and behavior 
modification are among the critical issues associated with the 
second step.11 Studies designed to include these approaches 
as a part of integrated care have resulted in favorable 
outcomes.12,13 The third step for managing AECOPD is the 
actual treatment itself. For mild symptoms of AECOPD, 
patients can be treated by unscheduled or emergency visits. 
Patients suffering from moderate-to-severe symptoms of 
AECOPD need to be hospitalized, and our study was designed 
to improve the quality of treatment at this final stage of the 
disease.
Some clinicians may feel an aversion to the uniform 
treatment menu of a clinical pathway, especially because the 
severity of disease symptoms varies greatly among individual 
patients. Indeed, it would be difficult to apply a clinical 
  pathway for acute medical conditions that included critically 
ill cases. It is a reasonable concern that the uniform treatment 
applied by the clinical pathway might result in a failure of 
treatment for such diseases as AECOPD, in which patients 
suffer from acute and severe conditions. The same treatment 
under the clinical pathway may be an over-treatment for some 
patients with mild disease or an under-treatment for some 
patients with severe symptoms. Furthermore, since AECOPD 
patients manifest qualitatively different clinical conditions, 
it can be argued that the treatments should be tailored to the 
condition of each patient. Although these concerns are valid 
and important to consider, it is also important to provide a 
simple, practical, and easily applicable plan for those prac-
titioners working at the forefront of medical services. We 
believe that our study provided evidence suggesting that a 
clinical pathway for AECOPD is both useful and practical.
One limitation of the present study is that it was not a 
randomized controlled trial which examined the impact of 
the clinical pathway as compared with AECOPD patients 
treated in other ways. In the UK National COPD Audit 2003, 
it was reported that the inpatient mortality rate was 7.4%, 
and the mean LOS for discharged patients was 8.3 days 
(median 6 days).2 In the 2005 Scandinavian audit of COPD 
hospitalizations, the overall in-hospital mortality was 3.7%, 
and the mean LOS was 8.6 days, although the LOS was 
longer than 10 days in 25% of the cases.14 In the US, Stein 
and colleagues examined the Nationwide Inpatient Sample International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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from the years 2000–2006 using five different algorithms 
and concluded that the in-hospital mortality was 2.0%–5.1%, 
and the median LOS was 4 days in patients hospitalized for 
AECOPD.15 Although the inpatient mortality in the Western 
studies can be considered comparable to our study, the LOS 
in the hospital, which is less than 10 days in most Western 
countries, is clearly longer in Japan. The LOS for all patients 
admitted to the Kyoto-Katsura Hospital during the period of 
our study was around 17 days, and this value is about the 
same as the average LOS for general acute hospitalizations 
in Japan. Any possible additional cost may be attributed to 
the longer stay in Japan. The reason for this difference can 
be attributed to the different systems of health care delivery 
between the Western countries and Japan. The problem in 
Japan is that the number of hospitals per capita is very high, 
but the number of staff per hospital bed is extremely low, and 
thus the shortage of employees in medical facilities poses a 
more serious problem.16 However, in Japan, there have been 
no reports on the therapeutic management of AECOPD, 
and therefore there are no references to compare the results 
presented in this study.
Some interventions, such as NPPV, have been shown 
to be effective in selecting patients enrolled in clinical 
trials. However, few studies are available on the use of 
NPPV as a routine standard medical protocol for patients 
with respiratory failure outside of these controlled trials. 
  According to the report from Schettino and colleagues,17 
87 patients with AECOPD were treated by NPPV in 2001, 
and the rate of intubation associated with NPPV failure 
was 24%.17 In our report, NPPV treatment was administered 
in 97 hospitalizations (40%), and the rate of intubation in our 
NPPV-treated cases was 8%. This favorable rate cannot be 
easily compared with the results reported by Schettino and 
colleagues, but evidence of the effectiveness of NPPV treat-
ment to control hypercapnic AECOPD is gradually accumu-
lating, and appears to be infiltrating clinical practice.
Ample evidence supports the effectiveness of pulmonary 
rehabilitation for stable COPD, but it remains controversial 
whether it should be applied during the acute phase 
of AECOPD. Evidence is now accumulating for the 
effectiveness of pulmonary rehabilitation during the recovery 
phase of AECOPD.7 However, the optimal time to start 
pulmonary rehabilitation has not been clearly established.18–20 
In the current clinical pathway, we implemented pulmonary 
rehabilitation during the acute phase, and started interventions 
with a physiotherapist immediately after the vital signs, such 
as fever, became stable. More clinical trials are needed to 
determine when to start pulmonary rehabilitation.
In some cases, we felt that the clinical pathway would be 
inappropriate due to frequent and recurrent exacerbations, 
and we intentionally avoided using it for the benefit of 
these specific patients. In addition, although our   clinical 
pathway was indicated for AECOPD inpatients, each 
  physician may have used different criteria to determine who 
should be   hospitalized. The absence of a uniform criterion 
for   hospitalization might have introduced a bias into the 
  outcomes of the clinical pathway in the present study.
Another limitation of the present study is that our limited 
data precluded us from examining other indices often used 
in the literature, such as the re-admission rate, the rate of 
relapses, treatment failure, and adverse effects. These param-
eters could be used to monitor the yearly performance of 
each hospital, and to compare each hospital against national 
standards. However, few studies have examined the cost of 
developing and implementing such an index, and how it may 
effectively change clinical practice to improve the outcomes 
of each hospital. The implementation of an inpatient clinical 
pathway for hospitalized asthmatic children led to a decrease 
in the LOS and a reduction in total cost, while improving 
the quality of care.21,22 Similarly, a clinical pathway for 
AECOPD should be evaluated from various viewpoints by 
comparing a group treated by the clinical pathway against 
a control group. Such a comprehensive evaluation should 
provide some basis to decide how a clinical pathway should 
be implemented for AECOPD. Another problem is that the 
present study was limited by the small number of cases 
of AECOPD included in the present series. However, this 
is all the patients with AECOPD admitted to this hospital 
during the study period. Although it has been reported that 
prevalence of COPD is similar to Western countries by a 
general population sample study,6 health care providers 
still feel that AECOPD is not so frequent. Since the COPD 
stage before AECOPD may affect the clinical pathway, the 
therapeutic interventions included in the clinical pathway 
could have been tailored to the disease severity of stable 
COPD before AECOPD.
In conclusion, the rate of dropouts from the clinical path-
way for AECOPD was low, and most of the dropouts were 
hypercapnic cases that required NPPV treatment. Although 
there are many differences in health care delivery between 
Japan and Western countries, it is also important to recognize 
that there are many issues remaining with regard to how clini-
cal pathways should be applied. Nevertheless, the applica-
tion of evidence-based medicine and the establishment of a 
standard treatment protocol based on clinical guidelines will 
certainly allow us to use the clinical pathway for AECOPD International Journal of COPD
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as an effective strategy. We believe that the clinical pathway 
for AECOPD can fill the gap between the guidelines and 
clinical practice.
Notes
The study was conducted at the Kyoto-Katsura Hospital, 
Kyoto, Japan, and partly funded by the NPO Medise in 
Japan.
Disclosure
The authors declare that they have no competing interests.
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